0.09(2.84%) Volume: 2,601,255 8:08PM EDT| Market Cap : 1.72 B | Enterprise Value : 1.79 B | P/E (TTM) : | P/B : 0.91 |
|---|
OPK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.58 |
OPK's Cash-to-Debt is ranked lower than
70% of the 886 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.53 vs. OPK: 0.58 ) Ranked among companies with meaningful Cash-to-Debt only. |
OPK'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48 Med: 18 Max: No Debt Current: 0.58 |
| Equity-to-Asset | 0.73 |
OPK's Equity-to-Asset is ranked higher than
65% of the 801 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. OPK: 0.73 ) Ranked among companies with meaningful Equity-to-Asset only. |
OPK'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02 Med: 0.71 Max: 0.96 Current: 0.73 |
| Debt-to-Equity | 0.08 |
OPK's Debt-to-Equity is ranked higher than
81% of the 540 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.32 vs. OPK: 0.08 ) Ranked among companies with meaningful Debt-to-Equity only. |
OPK'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.08 Max: 38.41 Current: 0.08 |
| Debt-to-EBITDA | -0.98 |
OPK's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.83 vs. OPK: -0.98 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
OPK'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.03 Med: -0.92 Max: 3.46 Current: -0.98 |
| Piotroski F-Score: 1 |
|
| Altman Z-Score: 1.04 |
|
| Beneish M-Score: -3.16 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -26.56 |
OPK's Operating Margin % is ranked lower than
80% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.96 vs. OPK: -26.56 ) Ranked among companies with meaningful Operating Margin % only. |
OPK'
s Operating Margin % Range Over the Past 10 Years
Min: -393.7 Med: -76.43 Max: -4.61 Current: -26.56 |
| Net Margin % | -28.93 |
OPK's Net Margin % is ranked lower than
80% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.73 vs. OPK: -28.93 ) Ranked among companies with meaningful Net Margin % only. |
OPK'
s Net Margin % Range Over the Past 10 Years
Min: -421.97 Med: -64.09 Max: -2.05 Current: -28.93 |
| ROE % | -15.02 |
OPK's ROE % is ranked lower than
76% of the 857 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.75 vs. OPK: -15.02 ) Ranked among companies with meaningful ROE % only. |
OPK'
s ROE % Range Over the Past 10 Years
Min: -467.26 Med: -18.03 Max: -1.23 Current: -15.02 |
| ROA % | -11.35 |
OPK's ROA % is ranked lower than
75% of the 888 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.29 vs. OPK: -11.35 ) Ranked among companies with meaningful ROA % only. |
OPK'
s ROA % Range Over the Past 10 Years
Min: -129.9 Med: -12.23 Max: -0.83 Current: -11.35 |
| ROC (Joel Greenblatt) % | -154.81 |
OPK's ROC (Joel Greenblatt) % is ranked lower than
81% of the 869 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 12.64 vs. OPK: -154.81 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
OPK'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6953.23 Med: -169.39 Max: -43.73 Current: -154.81 |
| 3-Year Revenue Growth Rate | 106.80 |
OPK's 3-Year Revenue Growth Rate is ranked higher than
99% of the 681 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.40 vs. OPK: 106.80 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
OPK'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 27.65 Max: 152 Current: 106.8 |
| 3-Year EBITDA Growth Rate | 4.40 |
OPK's 3-Year EBITDA Growth Rate is ranked lower than
61% of the 691 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 9.90 vs. OPK: 4.40 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
OPK'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: -6.55 Max: 45.5 Current: 4.4 |
| 3-Year EPS without NRI Growth Rate | -10.30 |
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 657 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 10.20 vs. OPK: -10.30 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
OPK'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -152.4 Med: 5.45 Max: 69.4 Current: -10.3 |
| Paul Tudor Jones 93,342 sh (New) Murray Stahl 58,941 sh (+1.36%) | Mario Gabelli 94,550 sh (unchged) | Joel Greenblatt Sold Out Ken Fisher 38,979 sh (-0.64%) |
| Jim Simons 1,615,691 sh (New) Murray Stahl 61,934 sh (+5.08%) | Mario Gabelli 94,550 sh (unchged) | Paul Tudor Jones Sold Out Ken Fisher 38,229 sh (-1.92%) |
| Murray Stahl 62,173 sh (+0.39%) | Mario Gabelli 94,550 sh (unchged) | Ken Fisher 32,379 sh (-15.30%) Jim Simons 1,077,491 sh (-33.31%) |
| Murray Stahl 78,019 sh (+25.49%) Ken Fisher 36,379 sh (+12.35%) | Mario Gabelli 86,800 sh (-8.20%) Jim Simons 159,991 sh (-85.15%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| Mario Gabelli | 2017-12-31 | Reduce -8.20% | $4.61 - $7.04 | $ 3.08 | -47% | 86,800 |  | |
| Ken Fisher | 2017-12-31 | Add 12.35% | $4.61 - $7.04 | $ 3.08 | -47% | 36,379 | | |
| Ken Fisher | 2017-09-30 | Reduce -15.30% | $5.88 - $7.11 | $ 3.08 | -51% | 32,379 | | |
| Ken Fisher | 2017-06-30 | Reduce -1.92% | $6.14 - $8 | $ 3.08 | -56% | 38,229 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!! What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:HRTX, TSE:4555, SHSE:603567, SHSE:603707, TSX:APH, SZSE:002737, SHSE:600781, XKRX:041960, FRA:DMP, BOM:540596, SZSE:300199, NAS:PAHC, TSE:8129, SHSE:603367, BOM:533573, NAS:RDUS, NYSE:DPLO, BOM:532872, SHSE:600267, SZSE:002390 » details | |
| Traded in other countries: | XCY.Germany, OPK.Israel, OPK.Mexico, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 0.90 |
OPK's PB Ratio is ranked higher than
88% of the 843 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.96 vs. OPK: 0.90 ) Ranked among companies with meaningful PB Ratio only. |
OPK'
s PB Ratio Range Over the Past 10 Years
Min: 0.89 Med: 7.96 Max: 800 Current: 0.9 |
| PS Ratio | 1.59 |
OPK's PS Ratio is ranked higher than
68% of the 784 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.25 vs. OPK: 1.59 ) Ranked among companies with meaningful PS Ratio only. |
OPK'
s PS Ratio Range Over the Past 10 Years
Min: 1.57 Med: 30.58 Max: 158.13 Current: 1.59 |
| EV-to-EBIT | -6.66 |
OPK's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 19.78 vs. OPK: -6.66 ) Ranked among companies with meaningful EV-to-EBIT only. |
OPK'
s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8 Med: -33.3 Max: 205.7 Current: -6.66 |
| EV-to-EBITDA | -11.11 |
OPK's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 16.59 vs. OPK: -11.11 ) Ranked among companies with meaningful EV-to-EBITDA only. |
OPK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6 Med: -34.9 Max: 547.8 Current: -11.11 |
| EV-to-Revenue | 1.65 |
OPK's EV-to-Revenue is ranked higher than
70% of the 810 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.38 vs. OPK: 1.65 ) Ranked among companies with meaningful EV-to-Revenue only. |
OPK'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6 Med: 32.1 Max: 161.4 Current: 1.65 |
| Current Ratio | 1.14 |
OPK's Current Ratio is ranked lower than
86% of the 772 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.56 vs. OPK: 1.14 ) Ranked among companies with meaningful Current Ratio only. |
OPK'
s Current Ratio Range Over the Past 10 Years
Min: 1.14 Med: 3.27 Max: 42.13 Current: 1.14 |
| Quick Ratio | 0.98 |
OPK's Quick Ratio is ranked lower than
79% of the 772 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.02 vs. OPK: 0.98 ) Ranked among companies with meaningful Quick Ratio only. |
OPK'
s Quick Ratio Range Over the Past 10 Years
Min: 0.98 Med: 3.27 Max: 42.13 Current: 0.98 |
| Days Inventory | 28.17 |
OPK's Days Inventory is ranked higher than
92% of the 765 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 116.78 vs. OPK: 28.17 ) Ranked among companies with meaningful Days Inventory only. |
OPK'
s Days Inventory Range Over the Past 10 Years
Min: 25.94 Med: 142.26 Max: 412.16 Current: 28.17 |
| Days Sales Outstanding | 56.59 |
OPK's Days Sales Outstanding is ranked higher than
68% of the 699 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 74.10 vs. OPK: 56.59 ) Ranked among companies with meaningful Days Sales Outstanding only. |
OPK'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86 Med: 111.95 Max: 243.4 Current: 56.59 |
| Days Payable | 43.74 |
OPK's Days Payable is ranked lower than
76% of the 640 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 73.92 vs. OPK: 43.74 ) Ranked among companies with meaningful Days Payable only. |
OPK'
s Days Payable Range Over the Past 10 Years
Min: 31.85 Med: 101.87 Max: 193.93 Current: 43.74 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.00 |
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 540 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -4.80 vs. OPK: -9.00 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
OPK'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3 Med: -13.85 Max: 0.4 Current: -9 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 1.56 | ||
| Price-to-Median-PS-Value | 0.05 |
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 692 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.08 vs. OPK: 0.05 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
OPK'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05 Med: 1.19 Max: 30 Current: 0.05 |
| Earnings Yield (Greenblatt) % | -15.03 |
OPK's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 888 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.96 vs. OPK: -15.03 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
OPK'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25.6 Med: -2.9 Max: 0.5 Current: -15.03 |
| Revenue (TTM) (Mil) $ | 1,067.50 |
|---|---|
| EPS (TTM) $ | -0.56 |
| Beta | 2.28 |
| Volatility | 36.51% |
| 52-Week Range $ | 2.66 - 7.90 |
| Shares Outstanding (Mil) | 253.76 |
| Dec18 | Dec19 | Dec20 | |
|---|---|---|---|
| Revenue (Mil $) | 1,286 | 1,441 | 1,671 |
| EBIT (Mil $) | |||
| EBITDA (Mil $) | |||
| EPS ($) | -0.13 | -0.05 | 0.19 |
| EPS without NRI ($) | -0.13 | -0.05 | 0.19 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | 12.00% | ||
| Dividends per Share ($) | |||
|
| Weekly CEO Buys Highlight Apr 16 2018 |
| Top Insider Buys Highlight for the Week of April 13 Apr 14 2018 |
| Weekly CEO Buys Highlight Apr 09 2018 |
| Weekly CEO Buys Highlight Apr 02 2018 |
| Weekly CEO Buys Highlight Mar 26 2018 |
| OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes Mar 23 2018 |
| CEO Buy Highlights for the Week Mar 19 2018 |
| Weekly CEO Buys Highlight Mar 12 2018 |
| Weekly CEO Buys Highlight Feb 26 2018 |
| Weekly CEO Buys Highlight Feb 19 2018 |
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP